Investigators at University Hospital zero in on atrial fibrillation therapy

Data detailed in "Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial" have been presented. "Atrial fibrillation patients with prior embolism have a high risk of vascular events in spite of anticoagulant therapy and elderly patients carry an additional risk. We analysed and compared vascular events-rate between older and younger than 75 years atrial fibrillation patients randomized to anticoagulant-alone or combined antiplatelet plus moderate-level anticoagulant therapy. A total of 967 patients stratified by age and the history of prior embolism were randomized to therapeutic doses of...

Want to see the full article?

• Purchase this article for only $3.00